Hetalox develops artificial intelligence solutions for the assessment and analysis of brain MRI studies, focusing on the early detection and monitoring of neurodegenerative and demyelinating diseases. By providing objective analysis, the technology enables timely treatment decisions and improves the quality of life for patients affected by conditions such as dementia and multiple sclerosis.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing prevalence of neurodegenerative and demyelinating diseases, such as dementia and multiple sclerosis, necessitates accurate and timely monitoring to inform treatment decisions. Traditional assessment methods for these conditions often lack the objectivity needed for consistent and reliable tracking of disease progression. This can lead to delays in appropriate treatment and negatively impact the quality of life for affected individuals.
Solution
Hetalox provides artificial intelligence (AI) solutions for the advanced assessment and analysis of brain MRI studies, enabling early detection and monitoring of neurodegenerative and demyelinating diseases. The technology offers objective analysis of MRI scans, facilitating accurate and fast disease detection and screening to identify patients susceptible to these conditions. By monitoring disease progression, Hetalox provides necessary information for selecting appropriate treatment methods and allows for immediate modification of therapy when necessary. This comprehensive analysis system aims to reduce the social impact of these diseases and improve the quality of life for patients worldwide.
Target Audience
The primary target audience includes healthcare professionals, such as neurologists and radiologists, involved in the diagnosis and management of neurodegenerative and demyelinating diseases.
Features
- AI-powered analysis of brain MRI studies for neurodegenerative and demyelinating diseases.
- Early detection capabilities for identifying patients susceptible to diseases like dementia and multiple sclerosis.
- Objective analysis and long-term monitoring of disease progression.
- Support for treatment decisions through comprehensive analysis.